Kyverna CTO granted 300,000 stock options

Kyverna Therapeutics’ Chief Technology Officer, Mayobanex Pujols, received a grant of stock options for 300,000 shares of common stock on February 9, 2026, with an exercise price of $8.08 per share.

Rhea-AI Filing Summary

Kyverna Therapeutics’ Chief Technology Officer, Mayobanex Pujols, received a grant of stock options for 300,000 shares of common stock on February 9, 2026, with an exercise price of $8.08 per share. These options were acquired as a compensatory award and are held directly.

According to the vesting terms, one-fourth of the option shares vest on February 9, 2027. The remaining shares vest in 1/48th increments each month thereafter, contingent on Pujols’ continuous service with Kyverna through each vesting date. After this grant, he beneficially owns 300,000 derivative securities in the form of these options.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Pujols Mayobanex

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	300,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 300,000 contracts (Direct)

Footnotes (1)

1. F1. 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive

FAQ

What insider transaction did Kyverna Therapeutics (KYTX) disclose in this Form 4?

Kyverna Therapeutics disclosed that Chief Technology Officer Mayobanex Pujols received a grant of 300,000 stock options on February 9, 2026. The options allow him to purchase Kyverna common stock at an exercise price of $8.08 per share, subject to a multi-year vesting schedule.

Who is the reporting person in the Kyverna Therapeutics (KYTX) Form 4 filing?

The reporting person is Mayobanex Pujols, who serves as Chief Technology Officer of Kyverna Therapeutics. He is identified as an officer, not a director or 10% owner. The filing covers a compensatory award of derivative securities in the form of stock options.

How many Kyverna Therapeutics (KYTX) options were granted to the CTO and at what price?

The CTO, Mayobanex Pujols, was granted 300,000 stock options linked to Kyverna common stock. These options carry an exercise price of $8.08 per share. Following this award, he beneficially holds 300,000 derivative securities directly in the form of these options.

When do Mayobanex Pujols’ Kyverna (KYTX) stock options begin vesting?

The vesting begins on February 9, 2027, when one-fourth of the option shares vest. After that initial cliff vesting, the remaining shares vest in 1/48th monthly installments, provided Pujols continues serving Kyverna through each monthly vesting date.

What is the full vesting schedule for the Kyverna (KYTX) options granted to the CTO?

The award vests over four years. One-fourth of the 300,000 option shares vest on February 9, 2027. The remaining shares vest in 1/48th increments each month thereafter, conditioned on the CTO’s continuous service with Kyverna through each vesting date.

How are the Kyverna Therapeutics (KYTX) options held by the CTO classified in the filing?

The options are reported as directly owned derivative securities. After the grant, 300,000 derivative securities remain beneficially owned. The transaction code is A, indicating a grant or award acquisition rather than an open-market purchase or sale of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pujols Mayobanex

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.08	02/09/2026		A		300,000		(1)	02/09/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive

	/s/ Marc Grasso, as Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.